CLDI
Calidi Biotherapeutics Inc.
NYSE MKT: CLDI · HEALTHCARE · BIOTECHNOLOGY
$0.22
+7.53% today
Updated 2026-04-30
Market cap
$2.46M
P/E ratio
—
P/S ratio
50.83x
EPS (TTM)
$-5.95
Dividend yield
—
52W range
$0 – $13
Volume
4.3M
Calidi Biotherapeutics Inc. (CLDI) Earnings
Quarterly earnings history, analyst estimates, and stock price reaction.
EPS beat streak
2 of 8
Last 8 quarters
Avg EPS surprise
-143.0%
Last 4 quarters
Revenue YoY growth
—
Most recent quarter
EPS YoY growth
-240.0%
Most recent quarter
Earnings surprise history (last 12 quarters)
Beat estimate Missed estimate
Quarterly EPS and revenue trend
Quarterly revenue EPS (diluted)
How the stock reacts to earnings
Avg 1-day reaction
-0.7%
Last 1 reports
Positive reaction rate
0%
0 of 1 quarters
Largest single-day move
-0.7%
2025-11-13
| Report date | EPS actual | Surprise | Close before | Close after | 1-day reaction |
|---|---|---|---|---|---|
| 2025-11-13 | $-2.21 | -952.4% | $1.51 | $1.50 | -0.7% |
Quarterly earnings history
| Fiscal quarter ending | EPS estimate | EPS actual | Surprise | Revenue | YoY revenue |
|---|---|---|---|---|---|
| 2025-09-30 | $-0.21 | $-2.21 | -952.4% | — | — |
| 2025-06-30 | $-0.21 | $-1.99 | -847.6% | — | — |
| 2025-03-31 | $-0.25 | $-0.18 | +28.0% | — | — |
| 2024-12-31 | $-0.09 | $-0.27 | -200.0% | $1.50M | — |
| 2024-09-30 | $-0.19 | $-0.65 | -242.1% | — | — |
| 2024-06-30 | $-0.19 | $-1.40 | -636.8% | — | — |
| 2024-03-31 | $-0.28 | $-0.20 | +28.6% | — | — |
| 2023-12-31 | $-0.20 | $-0.48 | -140.0% | — | — |
| 2023-09-30 | $-0.17 | $-0.14 | +17.6% | — | — |
| 2023-06-30 | — | $-0.43 | — | — | — |
| 2023-03-31 | — | $-27.02 | — | — | — |
| 2022-12-31 | $0.00 | $-0.26 | — | — | — |
Frequently asked questions
Has Calidi Biotherapeutics Inc. beaten earnings estimates?
Calidi Biotherapeutics Inc. has beaten Wall Street EPS estimates in 2 of its last 8 quarterly reports, with an average EPS surprise of -143.0% over the last 4 quarters.
How does CLDI stock react to earnings?
CLDI stock has moved an average of -0.7% in the trading day following earnings over its last 1 reports, with positive reactions in 0% of those quarters.